- ASSISTANT PROFESSOR | Population Health Science and Policy
PhD, University of Rome
MPH, Columbia University
Screening for Vascular Diseases:
Identifying individuals at risk for vascular disease and examine the cost effectiveness criteria that would bring the use of screening for vascular disease into common general practice.
Economic impact of medical errors.
Egorova NN, Gelijns AC, Moskowitz AJ, Emond JC, Krapf R, Lazar EJ, Guillerme S, Kaplan HS, Greco G. Process of Care Events in Transplantation: Effects on the Cost of Hospitalization. . Am J Transplant. 2010; 10: 1-8.
Greco G, Egorova N, Gelijns A, Moskowitz A, Zwolak R, Riles T, Manganaro A, Kent K. Development of a Novel Scoring Tool for the Identification of Large ≥ 5 cm Abdominal Aortic Aneurysms. Annals of Surgery Accepted 2010;.
Kent K, Zwolak R, Egorova N, Riles T, Manganaro A, Moskowitz A, Gelijns A, Greco G. Analysis of Risk Factors for Abdominal Aortic Aneurysm in a Cohort of More Than 3 Million Individuals. J Vasc Surg. Accepted 2010;.
Egorova N, Giacovelli J, Gelijns A, Greco G, Moskowitz A, McKinsey J, Kent K. Defining high-risk patients for endovascular aneurysm repair. J Vasc Surg 2009; 50: 1271-1279.
Egorova N, Giacovelli J, Greco G, Gelijns A, Kent K, McKinsey J. National Outcomes for the Treatment of Ruptured Abdominal Aortic Aneurysm: Comparison of Open Versus Endovascular Repairs. J Vasc Surg 2008; 48: 1092-1100.
Egorova N, Moskowitz A, Gelijns A, Weinberg A, Curty J, Rabin-Fastman B, Kaplan H, Cooper M, Emond J, Greco G. Managing the prevention of retained surgical instruments: what is the value of counting? . Annals of Surgery 2008; 247(13-1).
Morrissey NJ, Giacovelli J, Egorova N, Gelijns A, Moskowitz A, McKinsey J, Kent K, Greco G. Disparities in the Treatment and Outcomes of Vascular Disease in Hispanic Patients. J Vasc Surg 2007; 46: 971-978.
Nowygrod R, Egorova N, Greco G, Anderson P, Gelijns A, Moskowitz A, McKinsey J, Morrissey N, Kent K. Trends, complications, and mortality in peripheral vascular surgery. J Vasc Surg 2006; 43: 205-216.
Greco G, Egorova N, Anderson P, Gelijns A, Moskowitz A, Nowygrod R, Arons R, McKinsey J, Morrissey N, Kent K. Outcomes of endovascular treatment of ruptured abdominal aortic aneurysms. J Vasc Surg 2006; 43: 453-459.
Greco G, Egorova N, Gelijns A, Moskowitz A, Nowygrod R, Anderson P, Arons R, Parides M, McKinsey J, Kent K. Understanding the diffusion of vascular procedures: a quarter of a century experience. Trends in vascular surgery 2005;(Greenwood Academic): 443-454.
Ansari H, Greco G, Luban J. Cyclophilin A peptidyl–prolyl isomerase activity promotes ZPR1 nuclear export. Mol. Cell. Biol 2002; 22(PMC139809): 6993-7003.
Greco G, Pasqualini R, Schnapp LM. Matrix fibronectin increases HIV stability and infectivity. J. of Immunol 2002; 168: 5722-5729.
Tellier C, Greco G, Klotman M, Mosoian A, Cara A, Arap W, Ruoslahti E, Pasqualini R, Schnapp LM. Superfibronectin, a multimeric form of fibronectin increases HIV infection of primary CD4+ T lymphocytes. J. of Immunol 2000; 164: 3236-3245.
Greco G, Mackewicz C, Levy J. Sensitivity of HIV infection to various alpha, beta, and gamma chemokines. J. of General Virology 1999; 80: 2369-2373.
Greco G, Fujimura SH, Mourich D, Levy J. Differential effect of HIV isolates on beta-chemokine and Interferon gamma production and on cell proliferation. J. Virol 1999; 73(PMC103977): 1528-1534.
Greco G, Barker E, Levy J. Differences in HIV replication in CD4+ lymphocytes are not related to beta-chemokine production. AIDS Res. and Human Retroviruses 1998; 14: 1407-1411.
Gresser I, Greco G, Santini SM, Woodrow D, Mecchia M, Parlato S, Logozzi M, Venditti M, Maunoury MT, Belardelli F. Marked inhibition of Esb lymphoma metastases in mice using allogeneic immune and normal T lymphocytes and attempts to dissociate graft versus leukemia from graft-versus host disease. J. Interferon and Cytokine Research 1998; 18: 667-679.
Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Belardelli F. Cyclophosphamide -induced bystander effects on T cells and their importance for a successful tumor eradication in response to adoptive immunotherapy in mice. J. Clin. Invest 1998; 101: 429-441.
Locher CP, Blackbourn DJ, Barnett SW, Murthy KK, Cobb EK, Rouse S, Greco G, Reyes-Teran G, Brasky KM, Carey KD, Levy JA. Superinfection with Human Immunodeficiency Virus type 2 can reactivate virus production in baboons but is contained by a CD8+ T cell antiviral response. J. Infect. Dis 1997; 176: 948-959.
Mackewicz CE, Barker E, Greco G, Reyes-Teran G, Levy JA. Do beta-chemokines have clinical relevance in HIV infection?. J. Clin. Invest 1997; 100: 921-930.
Gresser L, Maury C, Kaido T, Bandu MT, Tovey MG, Maunoury MT, Fantuzzi L, Gessani S, Greco G, Belardelli F. The essential role of endogenous IFN-alfa/beta in the anti-metastatic action of sensitized T lymphocytes in mice injected with Friend erythroleukemia cells. International Journal of Cancer 1995; 63: 726-731.
Greco G, Gabriele L, Rozera C, Venditt M, Belardelli F, Proietti E. Correlation between the sensitivity or resistance to IL-2 and the response to Cyclophosphamide of 4 tumors transplantable in the same murine host.. International Journal of Cancer 1995; 62: 184-190.
Tritarelli E, Greco G, Testa U, Belardelli F, Peschle C, Proiett E. Combined Interleukin 1beta/Interleukin 6 treatment in mice: Synergistic myelostimulatory activity and myelorestorative effect after Cyclophosphamide-induced myelosuppression. Cancer Research 1994; 54: 6469-6476.
Gabriele L, Proietti E, Greco G, Venditti M, Gresser I, Schirrmacher V, Von Hoegen P, Testa U, Modest A, Cianfriglia M, Belardelli F. Isolation and characterization of a metastatic Eb-like tumor variant highly responsive to IL-2 and to combination cytokine therapy (IL-2/IL-1beta and IL-1beta/IFN-alfa/beta). Invasion and Metastasis 1993; 13: 147-162.
Proietti E, Tritarelli E, Gabriele L, Testa U, Greco G, Pelosi E, Gabbianelli M, Belardelli F, Peschle C. Synergistic myelostimulatory activity and protection against Cyclophosphamide-induced myelosuppression. Cancer Research 1993; 53: 569-576.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Greco did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.